{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:31:23Z","timestamp":1787020283341,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12745-1","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:02:16Z","timestamp":1723507336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed\/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States"],"prefix":"10.1186","volume":"24","author":[{"given":"Sophie","family":"Peloquin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Cymbalista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Del Fiacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E.","family":"Muehlenbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Lazure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"21","key":"12745_CR1","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1182\/blood-2017-10-764373","volume":"131","author":"XS Puente","year":"2018","unstructured":"Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood. 2018;131(21):2283\u201396.","journal-title":"Blood"},{"issue":"4","key":"12745_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/PPO.0000000000000534","volume":"27","author":"R Moia","year":"2021","unstructured":"Moia R, Patriarca A, Schipani M, Gaidano G. The biology of chronic lymphocytic leukemia: diagnostic and prognostic implications. Cancer J. 2021;27(4):266\u201374.","journal-title":"Cancer J"},{"issue":"6","key":"12745_CR3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94(6):710\u201325.","journal-title":"Am J Hematol"},{"key":"12745_CR4","doi-asserted-by":"crossref","unstructured":"Andreani G, Carra G, Lingua MF, Maffeo B, Brancaccio M, Taulli R, Morotti A. Tumor suppressors in chronic lymphocytic leukemia: from Lost partners to active targets. Cancers (Basel) 2020, 12(3).","DOI":"10.3390\/cancers12030629"},{"key":"12745_CR5","doi-asserted-by":"publisher","first-page":"204062072199055","DOI":"10.1177\/2040620721990553","volume":"12","author":"B Fakhri","year":"2021","unstructured":"Fakhri B, Andreadis C. The role of acalabrutinib in adults with chronic lymphocytic leukemia. Ther Adv Hematol. 2021;12:2040620721990553.","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"12745_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1080\/15384047.2018.1449616","volume":"19","author":"AR Mato","year":"2018","unstructured":"Mato AR, Samp JC, Gauthier G, Terasawa E, Brander DM. Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies. Cancer Biol Ther. 2018;19(7):636\u201343.","journal-title":"Cancer Biol Ther"},{"issue":"16","key":"12745_CR7","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647\u201356.","journal-title":"Blood"},{"issue":"10","key":"12745_CR8","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1080\/10428194.2017.1397665","volume":"59","author":"AO Ayed","year":"2018","unstructured":"Ayed AO, Parikh SA. Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. Leuk Lymphoma. 2018;59(10):2287\u201396.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"12745_CR9","first-page":"346","volume":"16","author":"GS Guru Murthy","year":"2023","unstructured":"Guru Murthy GS, Atallah E. Venetoclax-based treatment as Frontline Therapy for chronic lymphocytic leukemia. Hematol Oncol Stem Cell Ther. 2023;16(4):346\u201350.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"Suppl 1","key":"12745_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/hon.3145","volume":"41","author":"M Hallek","year":"2023","unstructured":"Hallek M. First line therapy of CLL. Hematol Oncol. 2023;41(Suppl 1):129\u201335.","journal-title":"Hematol Oncol"},{"key":"12745_CR11","doi-asserted-by":"crossref","unstructured":"Burkart M, Karmali R. Relapsed\/Refractory Mantle Cell Lymphoma: Beyond BTK inhibitors. J Pers Med 2022, 12(3).","DOI":"10.3390\/jpm12030376"},{"issue":"1","key":"12745_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40364-022-00357-5","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lu X, Li J, Miao Y. Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma. Biomark Res. 2022;10(1):17.","journal-title":"Biomark Res"},{"issue":"1","key":"12745_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01188-x","volume":"14","author":"M Wang","year":"2021","unstructured":"Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu KL, Bishton M, Collins GP, Eliadis P. Concurrent ibrutinib plus venetoclax in relapsed\/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol. 2021;14(1):1\u20138.","journal-title":"J Hematol Oncol"},{"issue":"30","key":"12745_CR14","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen P, Rawstron AC, Brock K, Mu\u00f1oz-Vicente S, Yates FJ, Bishop R, Boucher R, MacDonald D, Fegan C, McCaig A. Ibrutinib plus Venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722.","journal-title":"J Clin Oncol"},{"key":"12745_CR15","doi-asserted-by":"crossref","unstructured":"Eyre TA, Riches JC. The evolution of therapies Targeting Bruton tyrosine kinase for the treatment of chronic lymphocytic leukaemia: future perspectives. Cancers (Basel) 2023, 15(9).","DOI":"10.3390\/cancers15092596"},{"issue":"1","key":"12745_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33\u201344.","journal-title":"N Engl J Med"},{"issue":"10402","key":"12745_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study. Lancet. 2023;402(10402):641\u201354.","journal-title":"Lancet"},{"issue":"24","key":"12745_CR18","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, et al. Pirtobrutinib in Covalent Bruton tyrosine kinase inhibitor pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023;41(24):3988\u201397.","journal-title":"J Clin Oncol"},{"key":"12745_CR19","first-page":"1","volume":"42","author":"A Kumar","year":"2022","unstructured":"Kumar A, Eyre TA, Lewis KL, Thompson MC, Cheah CY. New directions for Mantle Cell Lymphoma in 2022. Am Soc Clin Oncol Educational Book. 2022;42:1\u201315.","journal-title":"Am Soc Clin Oncol Educational Book"},{"issue":"12","key":"12745_CR20","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","volume":"5","author":"CS Tam","year":"2021","unstructured":"Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, Kim WS, Rule S, Atwal SK, Wei R, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577\u201385.","journal-title":"Blood Adv"},{"issue":"3","key":"12745_CR21","doi-asserted-by":"publisher","first-page":"e578","DOI":"10.1634\/theoncologist.2019-0453","volume":"25","author":"I Henselmans","year":"2020","unstructured":"Henselmans I, van Laarhoven HWM, van Maarschalkerweerd P, de Haes H, Dijkgraaf MGW, Sommeijer DW, Ottevanger PB, Fiebrich HB, Dohmen S, Creemers GJ, et al. Effect of a skills Training for oncologists and a Patient Communication Aid on Shared decision making about palliative systemic treatment: a Randomized Clinical Trial. Oncologist. 2020;25(3):e578\u201388.","journal-title":"Oncologist"},{"key":"12745_CR22","first-page":"1","volume":"40","author":"FT Awan","year":"2020","unstructured":"Awan FT, Al-Sawaf O, Fischer K, Woyach JA. Current perspectives on therapy for chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:1\u201310.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"12745_CR23","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1634\/theoncologist.2016-0090","volume":"21","author":"D Hui","year":"2016","unstructured":"Hui D, Cerana MA, Park M, Hess K, Bruera E. Impact of oncologists\u2019 attitudes toward End-of-Life Care on patients\u2019 Access to Palliative Care. Oncologist. 2016;21(9):1149\u201355.","journal-title":"Oncologist"},{"key":"12745_CR24","unstructured":"Burrell N, Gross C. Quantitative research, purpose of. In: The sage encyclopedia of communication research methods edn. Edited by M. Allen: SAGE Publications Inc.; 2017: 1378\u20131380."},{"issue":"9","key":"12745_CR25","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/0142159X.2018.1483578","volume":"40","author":"DE Moore Jr","year":"2018","unstructured":"Moore DE Jr, Chappell K, Sherman L, Vinayaga-Pavan M. A conceptual framework for planning and assessing learning in continuing education activities designed for clinicians in one profession and\/or clinical teams. Med Teach. 2018;40(9):904\u201313.","journal-title":"Med Teach"},{"issue":"1","key":"12745_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/chp.20001","volume":"29","author":"DE Moore Jr","year":"2009","unstructured":"Moore DE Jr, Green JS, Gallis HA. Achieving desired results and improved outcomes: integrating planning and assessment throughout learning activities. J Continuing Educ Health Professions. 2009;29(1):1\u201315.","journal-title":"J Continuing Educ Health Professions"},{"issue":"6","key":"12745_CR27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","volume":"20","author":"WG Wierda","year":"2022","unstructured":"Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, et al. NCCN Guidelines(R) insights: chronic lymphocytic Leukemia\/Small lymphocytic lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022;20(6):622\u201334.","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"12745_CR28","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","volume":"19","author":"AD Zelenetz","year":"2021","unstructured":"Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, et al. NCCN Guidelines(R) insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021;19(11):1218\u201330.","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl4","key":"12745_CR29","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M, Committee EG. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl4):iv62\u201371.","journal-title":"Ann Oncol"},{"issue":"1","key":"12745_CR30","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1097\/HS9.0000000000000520","volume":"5","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Ghia P. EHA Endorsement of ESMO Clinical Practice guidelines for diagnosis, treatment, and follow-up of chronic lymphocytic leukemia. Hemasphere. 2021;5(1):e520.","journal-title":"Hemasphere"},{"issue":"1","key":"12745_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23\u201333.","journal-title":"Ann Oncol"},{"issue":"1","key":"12745_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11648\/j.ajtas.20160501.11","volume":"5","author":"I Etikan","year":"2016","unstructured":"Etikan I, Musa SA, Alkassim RS. Comparison of convenience sampling and purposive sampling. Am J Theoretical Appl Stat. 2016;5(1):1\u20134.","journal-title":"Am J Theoretical Appl Stat"},{"key":"12745_CR33","unstructured":"ICC\/ESOMAR: ICC\/ESOMAR (International Chamber of Commerce\/European Society for Opinion and Marketing Research.) International Code on Market, Opinion and Social Research and Data Analytics. In.: https:\/\/www.esomar.org\/what-we-do\/code-guidelines; 2016."},{"key":"12745_CR34","doi-asserted-by":"crossref","unstructured":"Shah NN, Peloquin S, Cymbalista F, Dreyling M, Murray S, Del Fiacco R, Lazure P. Challenges in Treatment Decisions and Patient-Provider Communication in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. American Society of Hematology (ASH) Annual Meeting, 10\u201313 December 2022. Blood 2022, 140(Supplement 1):13106\u201313108.","DOI":"10.1182\/blood-2022-166804"},{"key":"12745_CR35","doi-asserted-by":"crossref","unstructured":"Horgan D, Walewski J, Aurer I, Visco C, Gin\u00e9 E, Fetica B, Jerkeman M, Kozaric M, da Silva MG, Dreyling M. Tackling Mantle Cell Lymphoma in Europe. Healthcare: 2022. MDPI; 2022. p. 1682.","DOI":"10.3390\/healthcare10091682"},{"issue":"9","key":"12745_CR36","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1080\/10428194.2019.1574006","volume":"60","author":"SN Gopalsamy","year":"2019","unstructured":"Gopalsamy SN, Rosenthal KM, Ayers AA, Goy A, Leonard JP, Vose JM, Obholz KL, Armitage JO, Flowers CR. Clinical impact of internet-based tools to guide therapeutic decisions for mantle cell lymphoma. Leuk Lymphoma. 2019;60(9):2255\u201363.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"12745_CR37","first-page":"641","volume":"134","author":"A Quinquenel","year":"2019","unstructured":"Quinquenel A, Fornecker L-M, Letestu R, Ysebaert L, Fleury C, Lazarian G, Dilhuydy M-S, Nollet D, Guieze R, Feugier P. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood J Am Soc Hematol. 2019;134(7):641\u20134.","journal-title":"Blood J Am Soc Hematol"},{"key":"12745_CR38","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/cancers13061336","volume":"13","author":"M F\u00fcrstenau","year":"2021","unstructured":"F\u00fcrstenau M, Eichhorst B. Novel agents in chronic lymphocytic leukemia: new combination therapies and strategies to Overcome Resistance. Cancers. 2021;13:1336.","journal-title":"Cancers"},{"issue":"12","key":"12745_CR39","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679\u2013705.","journal-title":"Am J Hematol"},{"issue":"1","key":"12745_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/17474086.2020.1697226","volume":"13","author":"Y Khan","year":"2020","unstructured":"Khan Y, Lyou Y, El-Masry M, O\u2019Brien S. Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. Expert Rev Hematol. 2020;13(1):31\u20138.","journal-title":"Expert Rev Hematol"},{"key":"12745_CR41","unstructured":"Shanbhag S. Caring for patients with CLL in rural America. Managing lymphoma. In: Managing Lymphomas Newsletter vol. 161; 2021."},{"key":"12745_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-136205","volume":"136","author":"L Willis","year":"2020","unstructured":"Willis L, Abair T, Chen P, Westin J. Innovative, consequence-based Educational intervention improves Hematologists\/Oncologists skills using CAR T-Cell therapies for R\/R diffuse large B-Cell lymphoma. Blood. 2020;136:11\u20132.","journal-title":"Blood"},{"key":"12745_CR43","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/hon.54_2631","volume":"37","author":"L Willis","year":"2019","unstructured":"Willis L, Tanzola M. Using BTK inhibitors for chronic lymphotic leukemia online: education significantly improved the knowledge and competence of hematologists\/oncologists. Hematol Oncol. 2019;37:384\u20135.","journal-title":"Hematol Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12745-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T11:07:21Z","timestamp":1723547241000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12745-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12745"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12745-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All components of this study were approved by an international independent ethical review board (Veritas IRB, Canada, Tracking Number 2021-2930-9264-1), and all participants agreed to informed consent forms describing the nature and confidentiality of their participation, as well as their rights as a participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SP and PL are employees of AXDEV Group Inc. SM is CEO & founder of AXDEV Group Inc., AXDEV Global Inc., and AXDEV Europe GmbH. NS reports participation on advisory boards and\/or consultancy for Kite Pharma, BMS-Juno, TG therapeutics, Miltenyi Biotec, Lilly-LOXO, Epizyme, Incyte, Novartis, Janssen, Seattle Genetics, and Umoja; and research funding and honoraria from Miltenyi Biotec.FC reports participation on advisory boards and\/or consultancy for AbbVie, Lilly, Janssen, Astra Zeneca.MD reports participation on advisory boards for Astra Zeneca, Beigene, BMS\/Celgene, Gilead\/Kite, Janssen, Lilly\/Loxo, Novartis, Roche. He has research funding from Abbvie, Bayer, BMS\/Celgene, Gilead\/Kite, Janssen, Roche, and honoraria from Astra Zeneca, Beigene, Gilead\/Kite, Janssen, Lilly, Novartis, Roche. MD is an associate editor for HemaSphere.\u00a0NS, FC, and MD received research honoraria from AXDEV Global for their contribution to the study design, review of research tools, and interpretation of the findings from this study. RDF and CEM are employees of Eli Lilly and Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1003"}}